ArticleJornal de pediatria2026
hUC-MSCs regulating the balance of Th17/Treg in Henoch Schönlein purpura via STAT3 pathway.
Article in Jornal de pediatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study explores the relationship between T helper 17 (Th17)/regulatory T (Treg) cell balance, human umbilical cord mesenchymal stem cells (hUC-MSCs), and immune dysregulation in Henoch-Schönlein purpura (HSP).
methodsPeripheral blood and clinical data were collected from children with acute HSP and healthy controls. Th17/Treg-related transcription factors and cytokines were measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA). In vitro, human umbilical vein endothelial cells were stimulated with HSP serum and co-cultured with hUC-MSCs, with or without the signal transducer and activator of transcription 3 (STAT3) agonist colivelin TFA. STAT3 signaling, interleukin-6 (IL-6) expression, and endothelial migration were analyzed. In vivo, an ovalbumin-induced HSP rat model was treated with hUC-MSCs or stem cells plus colivelin TFA, followed by evaluation of pathological injury, STAT3 activation, and splenic Th17/Treg ratios.
resultsChildren with HSP exhibited significant Th17/Treg imbalance, with elevated RORγt and IL-17 and decreased FOXP3 and IL-10 (P < 0.05). In vitro, stem cells suppressed IL-6/STAT3 signaling, reduced STAT3 phosphorylation, and promoted endothelial repair, whereas colivelin TFA abolished these effects. In the rat model, stem cell transplantation alleviated inflammation in skin, kidney, joint, and intestinal tissues by downregulating the IL-6/STAT3/RORγt axis and restoring Th17/Treg balance; these benefits were negated by colivelin TFA.
conclusionTh17/Treg imbalance is an immunopathological feature of HSP. hUC-MSCs restore immune homeostasis by inhibiting STAT3 signaling, highlighting STAT3 as a potential therapeutic target and supporting further investigation of stem cell-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.